(Q44661518)

5 December 2017

title

Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis (English)

1 reference

5 December 2017

1 reference

1 reference

1

1 reference

5 December 2017

Heather E Leeper

2

1 reference

5 December 2017

Joon H Uhm

series ordinal

3

1 reference

5 December 2017

language of work or name

English

0 references

publication date

18 July 2013

1 reference

5 December 2017

1 reference

5 December 2017

volume

119

1 reference

5 December 2017

issue

19

1 reference

5 December 2017

page(s)

3489-3495

1 reference

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

Bevacizumab and daily temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

Pseudoprogression and pseudoresponse in the treatment of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

Glioblastoma survival in the United States before and during the temozolomide era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

inferred from DOI database lookup

7 January 2021

based on heuristic

FDA pulls approval for avastin in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28259

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.28259

1 reference

5 December 2017

1 reference